Hosted on MSN5d
FDA Warns People About The Serious Consequences Of Missed Notifications for Diabetes Patients
In this new age of technology, our lives have become heavily tangled with our electronics. Even when it comes to alerts about ...
Remote Patient Monitoring Market to Hit USD 56.94 Billion by 2030 with 12.7% CAGR | MarketsandMarkets™
The global remote patient monitoring market, valued at US$24.39 billion in 2023, is forecasted to grow at a robust CAGR of 12 ...
Le Lézard5d
Remote Patient Monitoring Market to Hit USD 56.94 Billion by 2030 with 12.7% CAGR | MarketsandMarketstm
The global remote patient monitoring market, valued at US$24.39 billion in 2023, is forecasted to grow at a robust CAGR of 12.7%, reaching US$27.72 billion in 2024 and an impressive US$56.94 billion ...
Why we need to rethink the discourse on body positivity in the age of Ozempic
As India awaits the launch of obesity drug, Mounjaro, the debate on weight loss drugs and body image continues ...
Remote Patient Monitoring Market to Hit USD 56.94 Billion by 2030 with 12.7% CAGR | MarketsandMarkets
The global remote patient monitoring market, valued at US$24.39 billion in 2023, is forecasted to grow at a robust CAGR of 12.7%, reaching US$27.72 ...
FDA shares warning on some smartphone-connected diabetes devices
According to the CDC, more than 38 million Americans have diabetes. This warning is for people who use diabetes apps like ...
Healio5d
FDA approves subcutaneous Merilog for glycemic control in diabetes
Please provide your email address to receive an email when new articles are posted on . The drug, which is the first rapid-acting biosimilar, is meant to treat blood sugar spikes at mealtimes.
The Financial Express3d
FDA gives nod to first rapid-acting insulin biosimilar for diabetes treatment
Diabetes is one of the major non-communicable diseases (NCDs). (Image Credits: Pixabay) The U.S. Food and Drug Administration ... which can lead to serious health problems for patients ...
Yahoo Finance4d
FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
"The FDA has now ... With diabetes, the pancreas doesn't make enough insulin to keep blood sugar levels in the normal range, which can lead to serious health problems for patients.
MedPage Today5d
FDA OKs First Rapid-Acting Insulin Biosimilar for Diabetes
Opens in a new tab or window The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced ...